8 Most Promising Biotech Stocks to Buy Now
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease.
Bridgebio Pharma Inc. (BBIO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 351,628 | $26,111,894 | +52% | 0.01% |
| 2. | Royce & Associates Chuck Royce | 232,923 | $17,296,862 | 0.17% | |
| 3. | Walleye Capital Will England | 228,593 | $16,975,316 | +4623% | 0.07% |
| 4. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 111,363 | $11,893,481 | -22% | 3.84% |
| 5. | Leucadia National Ian Cumming And Joseph Steinberg | 82,300 | $6,111,598 | -59% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 1,752 | $24,948.48 | 3,294 | 2021-12-29 | Filing | |
| $13.16 | 796 | $10,475.36 | 2,687 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 1,542 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 3,433 | 2021-12-28 | Filing | |
| $13.18 | 1,891 | $24,923.38 | 1,891 | 2021-12-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $68.35 | 950 | $64,930.32 | 4,358,447 | 2026-05-08 | Filing | |
| $67.35 | 5,076 | $341,845.76 | 4,359,397 | 2026-05-08 | Filing | |
| $66.65 | 13,974 | $931,374.09 | 4,364,473 | 2026-05-08 | Filing | |
| $68.35 | 950 | $64,930.32 | 555,686 | 2026-05-08 | Filing | |
| $67.35 | 5,077 | $341,913.10 | 556,636 | 2026-05-08 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,080,573 | $600,063,351 | 0.03% | |
| 2. | 7,759,495 | $576,220,099 | 0.01% | |
| 3. | 5,089,611 | $377,954,513 | 79.35% | |
| 4. | Ubs Group AgCALL | 3,863,500 | $286,903,510 | 0.04% |
| 5. | 2,026,821 | $150,511,728 | 0.02% |
News See All
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q1 2026 Earnings Call Transcript
Operator: Good afternoon. I will be your conference operator today. All lines have been placed on mute to prevent any background noise.
Billionaire Tom Steyer's 10 Stock Picks with Huge Upside Potential
Tom Steyer, the billionaire investor and founder of Farallon Capital, has undergone a profound evolution from a pioneer of absolute-return hedge fund strategies to a leading architect of climate capitalism...
Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 - Here's Why
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best high growth healthcare stocks to buy now. Mizuho lifted the price target on BridgeBio Pharma, Inc.
11 High Growth Healthcare Stocks to Buy Now
On March 26, Stephanie Link, Hightower chief investment strategist, appeared on CNBC's ‘Squawk Box’ to talk about the latest market trends, where investors can find opportunities, and the effects ...
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade
In a market report, JPMorgan raised its price target for BridgeBio Pharma Inc. (NASDAQ:BBIO) to $94 from $89 previously, marking a 26 percent upside potential from its latest closing price.
10 Stocks Investors Are Watching: WiPro, USAR, NIO, and More
Ten stocks soared higher on Tuesday, bucking a lackluster performance in the broader market, as investors took path from a flurry of positive developments including analyst ratings and earnings, among...
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating
On February 25, 2026, Truist analyst Danielle Brill raised the firm’s price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $95 from $86 and maintained a Buy rating on the shares.
10 Fastest Growing NASDAQ Stocks to Buy
High growth stocks have once again taken center stage, and major asset managers argue that earnings momentum remains the decisive factor. In its 2026 Year-Ahead Investment Outlook, J.P.
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential.
Hedge Fund Resource Center